Abstract
To support public health policymakers in Connecticut, we developed a county-structured compartmental SEIR-type model of SARS-CoV-2 transmission and COVID-19 disease progression. We calibrated this model to the local dynamics of deaths and hospitalizations and used a novel measure of close interpersonal contact frequency to approximate changes in infection transmission over time. In addition, we incorporated information on multiple time-varying parameters including the case fatality ratio, severity risk of incident cases, and length of hospital stay. In this paper, we describe the design, implementation, and calibration of a transmission model developed to meet the changing requirements of public health policymakers and officials in Connecticut. We describe methodology for producing short- and long-term projections of the epidemic evolution under uncertain future scenarios, as well as analytical tools for estimating epidemic features that are difficult to measure directly, such as cumulative incidence and effects of non-pharmaceutical interventions. The approach takes advantage of our unique access to Connecticut public health surveillance and hospital data to deliver COVID-19 projections tailored to the local context and responsive to the needs of local decision-makers.
Competing Interest Statement
FWC is a paid consultant to Whitespace Solutions.
Funding Statement
We acknowledge NIH/NICHD grant 1DP2HD091799-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis does not use patient-level data with personal identifiers.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated model specification and calibration procedure.
Data Availability
All data and code used in this analysis are available from https://crawford-lab.github.io/covid19_ct/.